Dual‐Functioning Metal‐Organic Frameworks: Methotrexate‐Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202404106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Burcu Karaca und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nanotechnology and Biotechnology, Istanbul Univeristy-Cerrahpasa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Methotrexate, Metal-Organic Frameworks, Gadolinium, Drug Carriers. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: TÜBİTAK ULAKBİM (Istanbul University-Cerrahpasa).
Abstract (Originalsprache)
Cancer remains a critical global health challenge, necessitating advanced drug delivery systems through innovations in materials science and nanotechnology. This study evaluates gadolinium metal‐organic frameworks (Gd‐MOFs) as potential drug delivery systems for anticancer therapy, particularly when combined with radiotherapy. Gd‐MOFs were synthesized using terephthalic acid and gadolinium (III) chloride hexahydrate and then loaded with methotrexate (MTX). Characterization via fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), magnetic resonance imaging (MRI), and X‐ray diffraction (XRD) confirmed their correct structure and stability. Effective MTX loading and controlled release were demonstrated. Anticancer effects were assessed on human healthy bronchial epithelial cells (BEAS‐2B) and human lung cancer cells (A549) using the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay under in vitro radiation therapy. MTX/Gd‐MOF combined with radiotherapy showed a greater reduction in cancer cell viability (41.89% ± 2.75 for A549) compared to healthy cells (56.80% ± 1.97 for BEAS‐2B), indicating selective cytotoxicity. These findings highlight the potential of Gd‐MOFs not only as drug delivery vehicles but also as radiosensitizers, enhancing radiotherapy efficacy and offering promising evidence for their use in combinatory cancer therapies to improve treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nanotechnology and Biotechnology, Istanbul Univeristy-Cerrahpasa, Istanbul, Turkey.
- Health Biotechnology Joint Research and Applications Center of Excellence, Istanbul, Turkey.
- Department of Biochemistry, School of Pharmacy, Bahcesehir University, Istanbul, Turkey.
- Vocational School of Health Services, Altınbas University, Istanbul, Turkey.
- Department of Chemical Engineering, Faculty of Engineering and Architecture, Istanbul Beykent University, Istanbul, Turkey.
- Boğaziçi University Center for Life Sciences and Tecnologies (LifeSci), Istanbul, Turkey.
Förderung
- TÜBİTAK ULAKBİM (Istanbul University-Cerrahpasa)
Zitieren
APA
Karaca, B., Sakarya, D., Siyah, P., Senisik, A. M., Kaptan, Y., Çavusoglu, F. C., Mansuroglu, D. S., Öztürk, S., Bayazit, S. S., & Barlas, F. B. (2025). Dual‐Functioning Metal‐Organic Frameworks: Methotrexate‐Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers. Chemistry – A European Journal. https://doi.org/10.1002/chem.202404106
Vancouver
Karaca B, Sakarya D, Siyah P, Senisik AM, Kaptan Y, Çavusoglu FC, et al. Dual‐Functioning Metal‐Organic Frameworks: Methotrexate‐Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers. Chemistry – A European Journal. 2025. doi:10.1002/chem.202404106
BibTeX
@article{Karaca2025,
author = {Karaca, Burcu and Sakarya, Deniz and Siyah, Pinar and Senisik, Ahmet M and Kaptan, Yasemin and Çavusoglu, Ferda C and Mansuroglu, Demet S and Öztürk, Sadullah and Bayazit, Sahika S and Barlas, Firat B},
title = {Dual‐Functioning Metal‐Organic Frameworks: Methotrexate‐Loaded Gadolinium MOFs as Drug Carriers and Radiosensitizers},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202404106}
}
EUVIMED